CD19 CAR-T cell therapy

CD19 CAR-T cell therapy is an immunotherapy approach that uses genetically modified T cells to target and destroy cancer cells expressing CD19, a protein found on B cells. The process involves collecting a patient's own T cells, genetically engineering them to express chimeric antigen receptors (CARs) that recognize CD19, expanding these modified cells in the laboratory, and then infusing them back into the patient. The 'feeding T cells' component likely refers to the expansion phase where T cells are cultured and multiplied before reinfusion. This therapy has shown remarkable efficacy in treating various B-cell malignancies, particularly when other treatments have failed.

Brand names

KymriahYescartaTecartusBreyanzi

Other names

tisagenlecleucelaxicabtagene ciloleucelbrexucabtagene autoleucellisocabtagene maraleucel